Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194957 | 1.00 | GPR183 (0.44) | GPR183EGFRERBB2MEN1KMT2A | |
| SCHEMBL827438 | 1.00 | GPR183 (0.44) | GPR183EGFRERBB2MEN1KMT2A | |
| SCHEMBL1194955 | 1.00 | GPR183 (0.44) | GPR183EGFRERBB2MEN1KMT2A | |
| SCHEMBL1194722 | 1.00 | GPR183 (0.44) | GPR183EGFRERBB2MEN1KMT2A | |
| SCHEMBL827453 | 0.92 | NFE2L2 (0.44) | MEN1KMT2ANFE2L2AHRPPARG | |
| SCHEMBL1194116 | 0.92 | NFE2L2 (0.44) | MEN1KMT2ANFE2L2AHRPPARG | |
| SCHEMBL1193128 | 0.92 | PTGES2 (0.40) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL1193131 | 0.92 | PTGES2 (0.40) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL827452 | 0.92 | NFE2L2 (0.44) | MEN1KMT2ANFE2L2AHRPPARG | |
| SCHEMBL5872228 | 0.84 | APP (0.39) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896401-B1 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | UNIV TEMPLE (US) | 2013-04-10 | — | — | EP | claimed |
| US-8143453-B2 | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-03-27 | — | — | US | claimed |
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-14 | — | — | US | claimed |
| EP-1896401-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | Temple University of the Commonwealth System of Higher Education (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006091870-A2 | UNSATURATED SULFIDES, SULFONES, SULFOXIDES AND SULFONAMIDES SYNTHESIS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1027330-A4 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030114538-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-06-19 | — | — | US | claimed |
| US-6548553-B2 | Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-15 | — | — | US | claimed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | claimed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | claimed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | claimed |
| US-9713597-B2 | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | ONCONOVA THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | ONCONOVA THERAPEUTICS, INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124828-A1 | Unsaturated Sulfides, Sulfones, Sulfoxides and Sulfonamides Synthesis | SULT2A1, SULT1A1, ARSA | GPR183 1965/4885EGFR 1291/4885ERBB2 2014/4885 |
| US-20030114538-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | GPR183 2303/4885EGFR 264/4885ERBB2 106/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | GPR183 2303/4885EGFR 264/4885ERBB2 106/4885 |
| US-20150238448-A1 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | ARSA, AHR, SULT2A1 | GPR183 1044/4885EGFR 2617/4885ERBB2 4060/4885 |
| US-20150265549-A1 | STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE | TTPA, EBP, ADH1A | GPR183 1811/4885EGFR 1457/4885ERBB2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.